Background: Our aim was to evaluate whether the cell of origin (COO) as defined by the Hans algorithm and MYC/BCL2 coexpression, which are the two main biological risk factors in elderly patients treated with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (R-CHOP), maintain their prognostic value in a large prospective clinical trial.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease with great variability in histopathological, molecular and clinical features [1] . In addition, the molecular subgroups of germinal center B-cell-like (GCB) and activated B-cell-like (ABC) DLBCL exhibit different prognostic outcomes following cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone (CHOP) chemotherapy with rituximab (R-CHOP) [2, 3] . This gene expression classification method has recently been adapted using a targeted expression approach on paraffinembedded tissue [4, 5] . Twelve years ago, these gene expression predictors were translated into routine immunohistochemistry (IHC)-based assays applicable to paraffin-embedded tissue using the well-known Hans algorithm [6] . However, published results regarding their value in predicting survival have been controversial [7] [8] [9] [10] [11] [12] [13] [14] . Few studies have used well-defined DLBCL populations with a standardized follow-up as in phase III trials [10] [11] [12] [13] [14] .
Some [15] [16] [17] [18] but not all studies [13, 19] have reported that other immunohistochemical biomarkers, such as MYC and BCL2 coexpression (a double expressor phenotype), are associated with poor prognosis in first-line DLBCL treatment. However, few reports have evaluated these biomarkers in phase III clinical trials [13, 18] , including only one trial [18] of patients treated with R-CHOP.
Our aim was to investigate the prognostic value of the cell of origin (COO) by IHC after evaluating its concordance with gene expression profiling (GEP) and MYC and BCL2 coexpression in a series of DLBCL patients treated with R-CHOP. We included patients participating in the phase III trial LNH03-6B conducted by the Lymphoma Study Association (LYSA).
Patients and methods

Patient selection
The LNH03-6B phase III randomized trial was designed to compare the efficacy of two schedules of R-CHOP (administered every 14 or 21 days) to treat previously untreated DLBCL with or without prophylactic darbepoetin alfa. A total of 600 patients were enrolled. Patients were eligible if they were 60-80 years of age and displayed at least one adverse prognostic factor according to the age-adjusted International Prognostic Index (aaIPI) and a good performance status (ECOG: 0-2). This trial was registered with ClinicalTrials.gov as trial number NCT00144755. We previously found no difference in survival between these two R-CHOP regimens [20] . This study complied with all provisions of the Declaration of Helsinki. All patients provided written informed consent to participate and provide tissue material for review and biological analysis.
Morphology
Eighty-eight percent (531 patients) of the cases were centrally reviewed to confirm the diagnosis of CD20-positive DLBCL among 514 patients. Tissue microarrays (TMAs) containing three representative 0.6-mm cores of routinely processed tissues from the centrally reviewed DLBCL cases were prepared (Beecher Instruments, Silver Spring, MD). Only patients with DLBCL and large specimens, including 299 patients overall, were selected for TMA.
Immunohistochemistry and in situ hybridization
Immunoperoxidase staining was centrally performed on an Ultra automated system (Roche Ventana, Tucson, AZ) using UltraVIEW detection kits and optimized protocols for CD10, BCL6, MUM1, BCL-2, and MYC staining as previously described [19] . In the absence of an internal positive control, immunostains were considered non-evaluable. The tissue core with the highest percentage of tumor cell staining was considered for analysis. GCB/non-GCB scoring according to the Hans algorithm [6] and MYC and BCL2 expression were evaluated. COO scoring was performed using TMA digitalization, and the spots for CD20/CD5/CD10/ BCL6/MUM1 could all be visualized on the same screen. In 14 out of the 299 cases, COO could not be assessed by IHC. The thresholds employed were 40% for MYC and 50% or 70% for BCL2 as previously reported [15, 16] . In addition, Epstein-Barr early RNA (EBER) in situ hybridization was performed.
COO molecular classification
Frozen tissue was analyzed using GeneChip Human Genome HGU133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA) as previously reported [21] . The 'unclassified' subgroup was defined as having samples not clearly identified as ABC or GCB subtypes. Sixty-two patients had both COO molecular classification from frozen tissue and COO immunohistochemical classification from the LNH03-6B TMA.
In addition, reverse transcription-multiplex ligation-dependent probe amplification (RT-MLPA) was performed to evaluate COO on the 62 formalin-fixed paraffin-embedded (FFPE) samples using a targeted molecular gene expression approach as recently described [5] .
Statistical analysis
Overall survival (OS) was measured from the date of randomization until death from any cause. Progression-free survival (PFS) was measured from the date of randomization until the date of disease progression, relapse or death from any cause. Survival analyses were performed using the log-rank test and expressed as Kaplan-Meier plots with appropriate 95% confidence intervals (CIs). Multivariate analyses were performed with a Cox proportional hazards regression model. Interactions between the treatment arm and biomarkers were evaluated in a restricted model, which considered only the treatment arm and the biomarker tested. Differences between the results of comparative tests were considered significant if the two-sided P value was <0.05. Statistical analyses were performed using SAS 9.2 software (SAS Institute, Cary, NC).
Results
Of the 602 patients included in the LNH03-6B trial, 285 were evaluable by the Hans algorithm. The median age of the patients was 70 (59-80) years. No significant differences in clinical characteristics between the selected patients and the entire LNH03-6B population were noted ( Table 1 ). The 3-year PFS was 58.9%, and the 3-year OS was 68.3%. A high IPI (3-5 versus 0-2) was significantly associated with low PFS and OS ( Figure 1A and B). Of the 285 patients, 3 expressed EBER RNA on tumor cells.
Immunophenotype and COO classification
Samples were classified as GCB (118 samples; 41%) or non-GCB (167 samples; 59%) according to the Hans algorithm (supplemen tary Table S1 and Figure S1 , available at Annals of Oncology online). BCL2 (70% threshold) was expressed in 61% of the tumors; this expression was not associated with the GCB or non-GCB subtype (P ¼ 0.62). MYC (40% threshold) was expressed in 34% of the cases and was not significantly associated within the GCB or non-GCB subtype (P ¼ 1.0). Coexpression of MYC and BCL2 was observed in 25% of cases. This double-expressor phenotype was marginally associated with the non-GCB phenotype (P ¼ 0.09).
Correlation of Hans algorithm score with COO defined by the transcriptome method as a gold standard or by RT-MLPA With reference to the transcriptome analysis on frozen tissue (62 patients), 30 patients were classified as GCB (39%) and 24 as ABC (46%); 8 were unclassified (15%) ( Table 2 ). After excluding the unclassified subtype, the overall concordance of the Hans algorithm score to the transcriptome method was 91% (49/54) with an almost perfect correlation according to a kappa test (0.81, 95% CI [0.655-0.969], P < 0.0001). 1 of the 19 cases that were CD10 negative and coexpressed BCL6 and MUM1 by IHC (non-GCB according to the Hans algorithm) was classified as GCB by GEP and probably stems from late GCB cells.
Of the 62 cases from the LNH03-6B that were tested by GEP from frozen tissue, 56 were evaluable by RT-MLPA from FFPE blocks (6 cases were not evaluable). The overall concordance of Hans scoring to the RT-MLPA method was 94%.
Survival analyses and immunohistochemical biomarkers
With reference to the univariate analyses ( Figure 1 and supple mentary Figure S2 , available at Annals of Oncology online), COO (Hans algorithm) and BCL2 (50% or 70% threshold) significantly impacted both PFS (P ¼ 0.002, P ¼ 0.007, and P ¼ 0.002, respectively) and OS (P ¼ 0.003, P ¼ 0.03, and P ¼ 0.01, respectively), whereas MYC expression or the MYC/BCL2 coexpression (40%/70% or 40%/50%) did not have a significant impact on either PFS (P ¼ 0.71, P ¼ 0.99, and P ¼ 0.92, respectively) or OS (P ¼ 0.75, P ¼ 0.96, and P ¼ 0.99, respectively). CD10 expression predicted a better PFS and OS (P ¼ 0.005 and P ¼ 0.006, respectively), whereas BCL6 and MUM1 expression significantly impacted only PFS (P ¼ 0.031 and P ¼ 0.0024, respectively).
With respect to the impact of BCL2 expression on survival among the GCB and non-GCB subtypes (Figure 2 ), patients with non-GCB DLBCL had significantly worse PFS (P ¼ 0.01) and OS (P ¼ 0.03) when tumors were BCL2 positive, whereas survival was not worse among patients with BCL2-positive GCB DLBCL.
With reference to the treatment arm (supplementary Figure  S3 , available at Annals of Oncology online), R-CHOP administered every 14 or 21 days (R-CHOP14 and R-CHOP21, respectively) predicted worse PFS and OS among patients with non-GCB DLBCL than among patients with GCB DLBCL (supplemen tary Figure S3A -D, available at Annals of Oncology online). In contrast, these two regimens did not differentially affect PFS and OS among BCL2-positive or BCL2-negative populations (supple mentary Figure S3E -H, available at Annals of Oncology online). However, although BCL2 expression significantly predicted worse PFS and OS among patients treated with R-CHOP14, the negative effect of BCL2 expression was attenuated among patients treated with R-CHOP21 compared with those treated with R-CHOP14 (supplementary Figure S3I -L, available at Annals of Oncology online). Nevertheless, there was no significant interaction between the treatment arm (R-CHOP14 versus R-CHOP21) and BCL2 expression (70% threshold) in relation to PFS (P ¼ 0.19) or OS (P ¼ 0.44).
All significant factors in the univariate analyses were included in a multivariate analysis for PFS and OS (Table 3) . Because CD10, MUM1 and BCL6 were used to calculate the Hans algorithm score, we used different Cox models. Both GCB/non-GCB phenotypes according to the Hans algorithm and BCL2 (70% threshold) had a significant prognostic impact on PFS (hazard ratio (HR)¼1.78, P ¼ 0.003 and HR ¼ 1.79, P ¼ 0.003, respectively) and OS (HR ¼ 1.85, P ¼ 0.005 and HR ¼ 1.67, P ¼ 0.002, respectively) independently of IPI. However, the Cox model did not show a significant prognostic impact on PFS or OS by any of the Hans biomarkers considered individually (CD10, BCL6, MUM1).
Discussion
We demonstrated that GCB/non-GCB according to the Hans algorithm and BCL2 expression predicted both PFS and OS in our patient sample. In our patients, MYC expression did not predict survival. This observation was surprising because the percentage of positive tumors in our patients (34%) was similar to that reported (31.8%) in the RICOVER trial using the same cut-off [18] among patients also treated with R-CHOP. In this trial, MYC expression predicted worse PFS and OS. Although the age inclusion criteria and median age were similar in the RICOVER and LNH03-6B trials (68 versus 70, respectively), fewer IPI 1-2 patients (24%) were included in our series than in the RICOVER series (64%), suggesting that clinically different cases of DLBCL 
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With number of subjects at risk and 95% confidence interval Figure 1 . Progression-free survival (PFS) and overall survival (OS) according to the International Prognostic Index (IPI) (A and B), Hans algorithm (C and D), BCL2 expression (70%) (E and F) and MYC/BCL2 coexpression (70%) (G and H). [13, 15, 19] . The C-MYC antibody (clone Y69) has been used only recently, and we cannot exclude that technical and analytical issues have not yet been validated as thoroughly as they have been for CD10, BCL6, MUM1, and BCL2 within multicentric international analyses, such as the Lunenburg consortium (LLBC) [22] . Indeed, in our patients, 16% of cases evaluable for COO by IHC were not evaluable for MYC by IHC, confirming that optimization of this new antibody is not yet well defined and that the known heterogeneity of MYC expression within a full slide might be missed when using TMA. Regarding the double-expressor (MYC and BCL2 coexpression) phenotype and the absence of prognostic value for survival, percentages of the doubleexpressor in our series (25%) were similar to those from two previously published studies [15, 16] (21% and 29%) that reported a strong prognostic effect of this expression. Nevertheless, neither of these two studies were conducted with patients involved in clinical trials, and it is likely that patient data retrieved from pathology files may include patients with very aggressive presentations who may not have been eligible for participation in clinical trials. In addition, in these two studies, this phenotype did not predict significantly worse PFS and OS in multivariate analyses among both training and validation populations.
Nevertheless, a strong prognostic value of BCL2 expression on survival independent of IPI and COO among patients treated with R-CHOP was demonstrated in our study. This information was previously demonstrated in various studies, at least regarding PFS [12, 13, 15] . Interestingly, although there was no interaction between the treatment arm and BCL2 expression, the attenuation of the effect among patients treated with R-CHOP 21 was consistent with our previous study with the LNH98-5 GELA trial [23] . The prognostic impact of BCL2 is particularly important in the era of targeted therapy, especially with the new anti-BCL2 drugs, as this expression may predict a better response to anti-BCL2 targeted agents.
Finally, we demonstrated that the Hans algorithm exhibits a good concordance (91% and 94%, respectively) with GEP and targeted RT-MLPA. This concordance is similar to that reported by Hans and Meyer (86%), which demonstrated a strong impact on survival of the GCB/non-GCB phenotypes [6, 8] . The high correlation between GEP and IHC in our study further highlights that our centralized automated technique, although applied to tissues from >80 different pathology centers, was optimized to detect CD10, BCL6 and MUM1 expression. In addition, digitalization of TMA and visualization of all the stains on the same 
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With number of subjects at risk and 95% confidence interval Figure 2 . Progression-free survival (PFS) and overall survival (OS) according to BCL2 expression among GCB (A and B) and non-GCB (C and D) DLBCL.
screen potentially facilitated the accuracy of scoring in this series. However, our concordance was evaluated in this trial on a small subpopulation and should be evaluated in a larger series. Therefore, in the era of targeted agents, such as lenalidomide, bortezomib and ibrutinib, which are used mainly for non-GCB or ABC DLBCL, IHC evaluating COO using the Hans algorithm may remain a useful tool, especially when the concordance of IHC with GEP is being evaluated, in addition to molecular targeted signatures on routine FFPE samples [4, 5] . Indeed, it is important to underline that GEP categorizes 14% of patients as unclassified [2] , while molecular targeted signatures categorize 22% as such [24] and that IHC may also act as a surrogate marker in such patients. 
